Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...

LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and ...

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune diseases, a continued appetite for next-generation obesity drugs and an increased ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...

Last Friday saw the USA’s Center for Medicare and Medicaid Services (CMS) announce the selection of 15 new drugs covered ...

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference. Meanwhile, Biogen proposes to acquire struggling neuro partner Sage, and ...

Kymera Therapeutics, Inc. has outlined its key objectives for 2025, emphasizing its strategy to advance a portfolio of oral ...

KYMR outlines plans to advance its immunology candidates. As of Dec. 31, 2024, KYMR had $850 million in cash that should fund its operations into mid-2027.

As for KT-621, the once-daily oral degrader of STAT6 protein is set to undergo a Phase 1b trial for atopic dermatitis (AD) in Q1, with data expected in Q4 2025. Phase 2b trials for KT-621 in AD ...

Shares of Kymera Therapeutics (NASDAQ:KYMR) spiked on Tuesday after the developer of oral protein degraders outlined its 2025 outlook at the ongoing J.P. Morgan Healthcare Conference. According to the ...

On Tuesday, Kymera Therapeutics shares leaped 12% following the biotechnology firm's update on its product pipeline. The New York-based company announced progress in its programs for atopic dermatitis ...